Brief: Surface Oncology Announces SRF388 Monotherapy Data In Non-Small Cell Lung Cancer
02/11/2022 10:22
Nov 2 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY ANNOUNCES PROMISING SRF388 MONOTHERAPY
DATA IN
NON-SMALL CELL LUNG CANCER, OPENING SECOND STAGE OF MONOTHERAPY
TRIAL AND NSCLC PEMBROLIZUMAB COMBINATION COHORT
* QTRLY LOSS PER SHARE $0.39
* CO FOCUSING RESOURCES ON ADVANCEMENT OF SRF388 AND SRF114,
EXTENDING CASH RUNWAY INTO Q2 2024
* AS OF SEPTEMBER 30, CASH, CASH EQUIVALENTS, MARKETABLE
SECURITIES WERE $146.4 MILLION, VERSUS $154.1 MILLION ON
DECEMBER 31, 2021
* Q3 EARNINGS PER SHARE VIEW $-0.47, REVENUE VIEW $80000.00
--
REFINITIV IBES DATA
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing